Catalio Capital Management, Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$478.7M
Q ending 2026-03-31
Prior quarter
$565.8M
Q ending 2025-12-31
Change
-15.4% QoQ · +16.4% YoY
Positions
41
reported holdings
Largest positions
All 41 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | DNTH | Shares | $47.0M | 560K |
| Bridgebio Pharma Inc | BBIO | Shares | $32.1M | 432K |
| Ascendis Pharma A/S | Shares | $29.5M | 129K | |
| Bristol-Myers Squibb Co | BMY | Shares | $25.5M | 421K |
| Syndax Pharmaceuticals Inc | SNDX | Shares | $24.4M | 1.0M |
| Gilead Sciences Inc | GILD | Shares | $22.8M | 164K |
| Terns Pharmaceuticals Inc | 430 | Shares | $21.6M | 409K |
| Definium Therapeutics Inc | DFTX | Shares | $19.6M | 1.0M |
| Soleno Therapeutics Inc | SLNOEUR | Shares | $19.3M | 578K |
| Boston Scientific Corp | BSX | Shares | $18.8M | 299K |
| Ultragenyx Pharmaceutical In | RARE | Shares | $17.8M | 851K |
| Incyte Corp | INCY | Shares | $17.1M | 182K |
| Cytokinetics Inc | CYTK | Shares | $14.2M | 216K |
| Natera Inc | NTRA | Shares | $14.2M | 71K |
| Corvus Pharmaceuticals Inc | CRVS | Shares | $13.0M | 892K |
| Structure Therapeutics Inc | GPCR | Shares | $12.3M | 255K |
| Mineralys Therapeutics Inc | MLYS | Shares | $11.9M | 439K |
| Edwards Lifesciences Corp | EW | Shares | $11.6M | 145K |
| Veradermics Inc | MANE | Shares | $11.0M | 174K |
| Adaptive Biotechnologies Cor | ADPT | Shares | $10.0M | 723K |
| Heartflow Inc | HTFL | Shares | $9.8M | 404K |
| Kalvista Pharmaceuticals Inc | 4XC1 | Shares | $8.6M | 427K |
| Uniqure Nv | Shares | $8.0M | 491K | |
| Disc Medicine Inc | IRON | Shares | $7.9M | 123K |
| Septerna Inc | SEPN | Shares | $7.1M | 294K |
| Abivax Sa | ABVX | Shares | $5.3M | 47K |
| Dyne Therapeutics Inc | DYN | Shares | $5.1M | 283K |
| Eledon Pharmaceuticals Inc | ELDN | Shares | $5.1M | 1.6M |
| Karyopharm Therapeutics Inc | KPTI | Shares | $5.0M | 898K |
| Supernus Pharmaceuticals | SUPN | Shares | $3.2M | 62K |
| Protara Therapeutics Inc | TARA | Shares | $3.0M | 580K |
| Phathom Pharmaceuticals Inc | PHAT | Shares | $2.8M | 248K |
| Newamsterdam Pharma Company | Shares | $2.7M | 84K | |
| Tyra Biosciences Inc | TYRA | Shares | $2.6M | 67K |
| Immunocore Hldgs Plc | IMCR | Shares | $2.5M | 84K |
| Fractyl Health Inc | GUTS | Shares | $2.5M | 5.5M |
| Hyperfine Inc | HYPR | Shares | $1.4M | 1.3M |
| Metagenomi Therapeutics Inc | MGX | Shares | $709K | 529K |
| Ataibeckley Inc | ATAI | Shares | $697K | 197K |
| Sensei Biotherapeutics Inc | FTH | Shares | $464K | 15K |
| Outset Med Inc | OM | Shares | $454K | 118K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.